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BACKGROUND: The best chemotherapy regimen for well- differentiated pancreatic
neuroendocrine tumours (pNETs) with a Ki-67 index ≥10% is still debated. We
evaluated the antitumour efficacy of various first-line chemotherapy regimens
(streptozocin based, platinum based, or dacarbazine/temozolomide based) in this
situation.
METHODS: In this retrospective multicentre study of the French Group of
Endocrine Tumours (GTE), we recruited consecutive patients with advanced well-
differentiated pNETs and a Ki-67 index ≥10% receiving chemotherapy between
2000 and 2012. The primary endpoint was progression-free survival (PFS)
according to RECIST.
RESULTS: Seventy-four patients (42 men, median age 55.5 years) were enrolled
from 10 centres. Fifty-one patients (69%) had grade 2 NET and 61 (82%) were
stage IV. Median overall survival was 36.3 months. Forty-four patients (59%)
received streptozocin-based, 18 (24%) platinum-based, and 12 (16%)
dacarbazine/temozolomide-based chemotherapy regimens. These 3 groups were
similar regarding age, functioning tumours, grade, the number of metastatic sites,
and surgery for primary tumours, but not regarding surgery for metastases and
time since diagnosis. Grade 3 NET (HR 2.15, 95% CI: 1.18-3.92, p = 0.012) and age
above 55 years (HR 1.84, 95% CI: 1.06-3.18, p = 0.030) were associated with
shorter median PFS in the multivariate analyses. Compared to streptozocin-based
chemotherapy, no difference was found in terms of PFS for the platinum-based or
for the dacarbazine/temozolomide-based chemotherapy regimen: median PFS was
7.2, 7.5, and 7.2 months, respectively (p = 0.51).
CONCLUSIONS: Patients with intermediate or highly proliferative well-
differentiated pNETs may benefit from 1 of the 3 chemotherapy regimens.
Increased age and grade 3 were associated with shorter median PFS. Randomised
studies searching for response predictors and the best efficacy-tolerance ratio are
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